This profile was last updated on .
Is this you? Claim your profile.
Johns Hopkins University
The Johns Hopkins Children's Center And The Johns Hopkins Hospital 600 North Wolfe Street
Johns Hopkins Medicine (JHM), headquartered in Baltimore, Maryland, is a $7 billion integrated global health enterprise and one of the leading academic health care systems in the United States. JHM unites physicians and scientists of the Johns Hopkins Uni...
Find other employees at this company (33,328)
(35 Total References)
Ie-Ming Shih, M.D., ...
Ie-Ming Shih, M.D., Ph.D.
Departments of Pathology, Oncology and Gynecology/Obstetrics
Johns Hopkins University School of Medicine
Dr. Shih is a Professor of Pathology, Gynecology/Obstetrics and Oncology at the Johns Hopkins University School of Medicine, Baltimore, Maryland.
He is a board-certified attending pathologist in the Division of Gynecologic Pathology at the Johns Hopkins Hospital.
Dr. Shih obtained his MD degree from the Taipei Medical University, Taiwan, and received his PhD in biomedical studies at the University of Pennsylvania.
completed residency training in Anatomic Pathology followed by a Gynecologic Pathology fellowship at the Johns Hopkins Hospital
spent two post-doctoral years in the laboratory of Bert Vogelstein studying molecular cancer genetics.
Dr. Shih was appointed to the faculty of Johns Hopkins in 2000 and became a professor in 2008.
Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers
Departments of Pathology and Oncology, Johns Hopkins Medical Institutions, Baltimore, MD
Ie-Ming Shih, Johns ...
Ie-Ming Shih, Johns Hopkins Medical Institutes, Baltimore, MD
Presented By Dr. Ie-Ming ...
Presented By Dr. Ie-Ming Shih
Johns Hopkins Hospital , Baltimore, MD
Women at Risk
"Now there's the possibility that testing for NAC-1 protein in cancer tissue removed during surgery might identify women most at risk for recurrence and guide doctors and patients to greater vigilance and extended therapy," said Ie-Ming Shih, M.D., Ph.D., associate professor of pathology at Johns Hopkins Kimmel Cancer Center.The research also suggests that drugs capable of blocking NAC-1 activity may be a useful strategy in preventing and treating recurrences as well.A report on the research, the first to link NAC-1 to cancer, appears in the December 5 issue of the Proceedings of the National Academy of Sciences. "Because recurrent cancers are often what really kill patients, and most ovarian cancer is diagnosed when it's already advanced, our findings offer women a better chance of catching or preventing recurrent disease early and increasing survival," says Shih.
says that in the future, drugs that mimic N130 can be used to treat cancer.This research was supported by the Department of Defense and the National Institutes of Health